See more : Arctic Minerals AB (publ) (ARCT.ST) Income Statement Analysis – Financial Results
Complete financial analysis of TransMedics Group, Inc. (TMDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TransMedics Group, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Varopakorn Public Company Limited (VARO.BK) Income Statement Analysis – Financial Results
- De Nora India Limited (DENORA.BO) Income Statement Analysis – Financial Results
- Good Energy Group PLC (GOOD.L) Income Statement Analysis – Financial Results
- Softronic AB (publ) (SOF-B.ST) Income Statement Analysis – Financial Results
- Toei Animation Co.,Ltd. (TOEAF) Income Statement Analysis – Financial Results
TransMedics Group, Inc. (TMDX)
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.69M | 6.21M |
| Cost of Revenue | 87.53M | 28.19M | 9.10M | 9.00M | 9.74M | 7.28M | 5.55M | 5.44M |
| Gross Profit | 154.09M | 65.27M | 21.16M | 16.64M | 13.86M | 5.73M | 2.14M | 766.00K |
| Gross Profit Ratio | 63.77% | 69.84% | 69.92% | 64.88% | 58.73% | 44.05% | 27.81% | 12.34% |
| Research & Development | 63.27M | 26.81M | 22.30M | 18.83M | 19.87M | 13.66M | 14.96M | 15.64M |
| General & Administrative | 119.55M | 51.69M | 38.28M | 24.19M | 21.52M | 12.32M | 7.61M | 0.00 |
| Selling & Marketing | 0.00 | 18.21M | 8.60M | 931.00K | 2.07M | 1.02M | 674.00K | 0.00 |
| SG&A | 119.55M | 69.90M | 38.28M | 24.19M | 23.60M | 12.32M | 7.61M | 8.12M |
| Other Expenses | 0.00 | -1.00M | -877.00K | 1.65M | 790.00K | -213.00K | 548.00K | 5.00K |
| Operating Expenses | 182.82M | 96.71M | 60.59M | 43.02M | 43.47M | 25.97M | 22.56M | 23.75M |
| Cost & Expenses | 270.35M | 124.90M | 69.69M | 52.02M | 53.21M | 33.25M | 28.11M | 29.20M |
| Interest Income | 12.50M | 900.00K | 100.00K | 700.00K | 1.00M | 0.00 | 548.00K | 5.00K |
| Interest Expense | 10.79M | 3.73M | 3.87M | 3.99M | 4.35M | 2.42M | 1.07M | 979.00K |
| Depreciation & Amortization | 8.18M | 4.20M | 2.65M | 1.58M | 1.22M | 769.00K | 630.00K | 426.00K |
| EBITDA | -7.60M | -28.96M | -38.49M | -23.15M | -27.93M | -20.23M | -19.09M | -22.66M |
| EBITDA Ratio | -3.15% | -34.71% | -133.19% | -96.46% | -122.07% | -151.19% | -250.46% | -363.26% |
| Operating Income | -28.73M | -31.44M | -39.43M | -26.38M | -29.60M | -20.24M | -20.43M | -22.99M |
| Operating Income Ratio | -11.89% | -33.64% | -130.29% | -102.91% | -125.42% | -155.47% | -265.79% | -370.20% |
| Total Other Income/Expenses | 2.06M | -4.73M | -4.75M | -2.33M | -3.90M | -3.48M | -365.00K | -1.08M |
| Income Before Tax | -26.67M | -36.17M | -44.18M | -28.72M | -33.51M | -23.72M | -20.79M | -24.07M |
| Income Before Tax Ratio | -11.04% | -38.70% | -145.99% | -112.00% | -141.95% | -182.18% | -270.54% | -387.58% |
| Income Tax Expense | -1.64M | 66.00K | 36.00K | 32.00K | 40.00K | 41.00K | 32.00K | 984.00K |
| Net Income | -25.03M | -36.23M | -44.22M | -28.75M | -33.55M | -23.76M | -20.82M | -24.07M |
| Net Income Ratio | -10.36% | -38.77% | -146.11% | -112.13% | -142.12% | -182.50% | -270.96% | -387.58% |
| EPS | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| EPS Diluted | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Weighted Avg Shares Out | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
| Weighted Avg Shares Out (Dil) | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TransMedics: Maintaining A Neutral Stance After A Difficult Q3
TMDX which was outperforming the S&P500 by 6x in August, is now only generating half the returns of the benchmark on a YTD basis. The Q3 event appears to have spooked investors and we dive in to cover some of...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics...
TransMedics: Every Hero Becomes A Bore At Last
TransMedics Group, Inc. faces significant challenges due to aircraft maintenance issues and rising aviation costs, leading to a 42% stock price drop and a HOLD rating. Revenue shortfall is attributed to a national decline in transplant volumes and reduced service...
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
Did TransMedics Group, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TMDX
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024,...
TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
TransMedics shares fell 25% pre-market after a disappointing Q3 report, missing revenue and EPS estimates, with management failing to manage expectations. Despite the poor quarter, the long-term opportunity remains large, and a good Q4 could significantly boost shares. Management's poor...
These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results
TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday.
TransMedics Stock Crashes After Earnings Disappointment. Time to Load Up the Boat?
Is this the buy-the-dip opportunity investors have been waiting for?
TransMedics Group Posts Weak Results, Joins Harmonic, Crocs, D.R. Horton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Tuesday.
Source: https://incomestatements.info
Category: Stock Reports